Bayer
No enriched coverage for $BAYN.DE in the last 7 days.
German stocks rose, ending a 4-day losing streak, with the DAX up 0.07% to 26,030.50. Gains were seen in Continental, BMW, and others, while CTS Eventim fell 1.3% after mixed earnings. Germany's manufacturing PMI rose to 54.1, beating expectations, while services PMI fell to 48.5, missing forecasts.
Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
Recent BAYN.DE coverage spans macro economy and financial news.
Price decline reflects sector weakness rather than company‑specific news.
Regulatory approval for a differentiated imaging agent is a positive catalyst, potentially supporting Bayer’s diagnostics/imaging product pipeline.
alphai scores every news story that mentions BAYN.DE with an AI model for sentiment and relevance, and aggregates insider trades from Bayer's SEC EDGAR Form 4 filings. Figures refresh continuously.
German stocks rose, ending a 4-day losing streak, with the DAX up 0.07% to 26,030.50. Gains were seen in Continental, BMW, and others, while CTS Eventim fell 1.3% after mixed earnings. Germany's manufacturing PMI rose to 54.1, beating expectations, while services PMI fell to 48.5, missing forecasts.
2 min readBiotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min read